H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com

H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics and raised its price target to $4.00, with the stock trading at $2.91 versus a 52-week high of $3.10. The article highlights Ovid’s KCC2 pipeline progress, including OV350 and OV4071, and notes recent Q4 2025 results that beat expectations with EPS of $0.06 versus -$0.1137 and revenue of $718,000 versus $80,670. Additional bullish analyst commentary from B.Riley and Leerink reinforces improving sentiment around the company’s neurology drug portfolio.

Analysis

OVID is functioning less like a classic single-asset biotech and more like a platform optionality trade: the market is paying for a credible shot at multiple shots on goal, but the implied probability is now much higher than a year ago. That matters because the next leg is likely to be driven by data quality and formulation execution, not headline enthusiasm; once a stock has already rerated this far, incremental upside usually comes from de-risking events that compress the probability-weighted discount rate rather than from narrative expansion.

The second-order winner may be the company’s future partnering leverage. If the oral direct-activator program looks durable, larger neurology players with thin late-stage CNS pipelines could become more aggressive on deals, especially if they can buy time and differentiation without paying for full clinical infrastructure. The likely loser is any adjacent CNS program lacking a clean biomarker or mechanistic story, because capital tends to migrate toward the most legible platform when investors re-rate an entire modality.

Near term, the main risk is not scientific failure but expectation inflation. A stock this extended can sell off sharply on merely “good but not transformative” updates, and the market may be underestimating how quickly enthusiasm can unwind if dosing, tolerability, or oral PK limits appear in chronic use. The path dependence is important: over the next 1-3 quarters, the shares likely trade on whether the company can show translational continuity from mechanism to human signal, not on broader biotech beta.

Consensus appears to be treating the move as early innings, but the more contrarian read is that the easy part of the rerating may already be done. If the company is right, the upside is substantial over 12-24 months; if not, the downside can be violent because high-beta platform names lose multiple turns of EV on any hint that the first-in-class story is not cleanly reproducible. In other words, this is increasingly a timing trade around catalysts, not a passive hold.

Key Decisions for Investors

• Hold or initiate a tactical long only into a defined catalyst window over the next 1-2 quarters; use tight risk controls because post-rerate biotech names can retrace 20-30% on non-transformational updates.
• Prefer call spreads over outright equity for exposure to OVID over 3-6 months: bullish if the platform continues to de-risk, but capped downside is more attractive after a 900% move.
• If already long, trim 25-40% into strength and retain a core position for the 12-24 month partnering/data optionality; the risk/reward has shifted from asymmetric upside to event-driven compounding.
• Pair trade idea: long OVID / short a basket of lower-quality, non-differentiated CNS development names over the next 6-12 months, betting that capital concentrates into the cleanest mechanistic story.
• Watch for a partnering announcement or oral-program data as the next major inflection; if neither materializes within 2-3 quarters, reassess thesis because valuation support may weaken quickly.